• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    4/8/26 8:10:40 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FRMM alert in real time by email
    false 0001690080 0001690080 2026-04-08 2026-04-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): April 8, 2026

     

     

    FORUM MARKETS, INCORPORATED

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38105   90-1890354
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2875 South Ocean Blvd., Suite 200
    Palm Beach, FL
      33480
    (Address of Principal Executive Offices)   (Zip Code)

     

    (650) 507-0669
    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   FRMM   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Second Amended and Restated Sales Agreement

     

    As previously reported, on August 13, 2025, Forum Markets, Incorporated (formerly ETHZilla Corporation, which was formerly 180 Life Sciences Corp.) (the “Company”) entered into a Sales Agreement (the “Initial Sales Agreement”) with Clear Street LLC (“Clear Street”) to sell from time to time through Clear Street, acting as sales agent for the Company’s “at the market offering” program, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) pursuant to the Company’s registration statement on Form S-3 (File No. 333-288194) (the “June Registration Statement”) and the prospectus supplement initially filed on August 13, 2025 (the “Initial Prospectus Supplement”). On August 22, 2025, the Company entered into an Amended and Restated Sales Agreement (the “Amended Sales Agreement”) with Clear Street to, among other things, change the registration statement and prospectus supplement pursuant to which sales of the Common Stock were to be made to the registration statement on Form S-3ASR (File No. 333-289811) (the “WKSI Registration Statement”) and the prospectus supplement initially filed on August 22, 2025 (the “WKSI Prospectus Supplement”). On November 14, 2025, the Company entered into an Amended and Restated Sales Agreement (the “Second Amended Sales Agreement”) with Clear Street and TCBI Securities, Inc., doing business as Texas Capital Securities (“Texas Capital Securities”, and together with Clear Street, the “Agents”), which, among other things, amended and restated the Amended Sales Agreement to include Texas Capital Securities as a sales agent.

     

    On April 8, 2026, the Company entered into a Second Amended and Restated Sales Agreement (the “Second Amended and Restated Sales Agreement”) with the Agents to cease all sales of Common Stock pursuant to the WKSI Registration Statement and WKSI Prospectus Supplement and to transition the program back to the June Registration Statement and Initial Prospectus Supplement. From and after the date of the Second Amended and Restated Sales Agreement, the Company will not sell any Common Stock pursuant to the WKSI Registration Statement and WKSI Prospectus Supplement, and any future sales will be made pursuant to the June Registration Statement and Initial Prospectus Supplement. There were no other material changes to the terms of the Second Amended Sales Agreement as a result of such amendments. 

     

    The foregoing description of the Second Amended and Restated Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Second Amended and Restated Sales Agreement, a copy of which is filed herewith as Exhibit 10.1 and is incorporated in this Item 1.01 by reference. 

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.  Exhibit
    10.1  Second Amended and Restated Sales Agreement, dated April 8, 2026 by and among Forum Markets, Incorporated, Clear Street LLC, and TCBI Securities, Inc. d/b/a Texas Capital Securities.
    23.1  Consent of M&K CPA’s, PLLC, independent registered public accounting firm.
    104  Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      FORUM MARKETS, INCORPORATED
           
    Date: April 8, 2026 By: /s/ McAndrew Rudisill
        Name:  McAndrew Rudisill
        Title: Chief Executive Officer

     

    2

     

    Get the next $FRMM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRMM

    DatePrice TargetRatingAnalyst
    4/7/2026$5.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $FRMM
    SEC Filings

    View All

    SEC Form EFFECT filed by Forum Markets Incorporated

    EFFECT - FORUM MARKETS Inc (0001690080) (Filer)

    4/10/26 12:15:03 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Markets Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - FORUM MARKETS Inc (0001690080) (Filer)

    4/8/26 9:06:39 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Forum Markets Incorporated

    424B3 - FORUM MARKETS Inc (0001690080) (Filer)

    4/8/26 8:29:06 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Forum Markets with a new price target

    The Benchmark Company initiated coverage of Forum Markets with a rating of Speculative Buy and set a new price target of $5.00

    4/7/26 8:46:27 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dalton Angela

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    4/6/26 8:15:10 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dalton Angela

    3 - FORUM MARKETS Inc (0001690080) (Issuer)

    4/6/26 7:46:15 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Edwards Michael A

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    4/3/26 7:10:48 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forum Announces Initiation of Analyst Coverage by Benchmark

    Benchmark Initiates with Speculative Buy Rating and $5.00 Price TargetPALM BEACH, Fla., April 7, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced that The Benchmark Company, LLC, a StoneX company, has initiated coverage of Forum's common stock with a Speculative Buy rating and a price target of $5.00 per share. The initiation, published by Benchmark analyst, Mark Palmer, on April 7, 2026, highlights Forum's position as a pure-play early m

    4/7/26 2:43:00 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Reports Fourth Quarter and Full Year 2025 Financial Results

    Company Introduces 2026 Guidance as RWA Tokenization Platform Begins to Scale PALM BEACH, Fla., March 31, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum" or the "Company"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today reported financial results for the fourth quarter and full year ended December 31, 2025. "In less than a year, Forum has moved from concept to execution: from building the infrastructure, establishing key partnerships, and validating our technology, to generating revenu

    3/31/26 9:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum to Present at Sidoti's Small-Cap Virtual Investor Conference on March 18

    PALM BEACH, Fla., March 12, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced that McAndrew Rudisill, chairman and CEO, and John Kristoff, senior vice president, corporate communications and investor relations, are expected to participate in the Sidoti Small-Cap Virtual Investor Conference on Wednesday, March 18, 2026.  The company will participate in a group presentation at 2:30 PM EDT and will also host virtual one-on-one meeti

    3/12/26 9:00:00 AM ET
    $ETHZ
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Leadership Updates

    Live Leadership Updates

    View All

    Forum Appoints Robert Spake as General Counsel

    PALM BEACH, Fla., March 3, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced the appointment of Robert Spake as the company's general counsel. Spake's deep legal expertise in capital markets, tokenization, and regulatory compliance strengthens Forum's leadership team and sharpens its focus on launching compliant, institutionally structured real-world asset products within evolving regulatory frameworks.  "Robert joins Forum at a pivotal mo

    3/3/26 9:00:00 AM ET
    $ETHZ
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Financials

    Live finance-specific insights

    View All

    Forum Reports Fourth Quarter and Full Year 2025 Financial Results

    Company Introduces 2026 Guidance as RWA Tokenization Platform Begins to Scale PALM BEACH, Fla., March 31, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum" or the "Company"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today reported financial results for the fourth quarter and full year ended December 31, 2025. "In less than a year, Forum has moved from concept to execution: from building the infrastructure, establishing key partnerships, and validating our technology, to generating revenu

    3/31/26 9:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care